Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as HEC-007 injection
HEC-007 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| SAD Stage: HEC-007 Injection | EXPERIMENTAL | Administered once |
| SAD Stage: Placebo | PLACEBO_COMPARATOR | Administered once |
| MAD Stage: HEC-007 injection | EXPERIMENTAL | Administered for multiple dose |
| MAD Stage: Placebo | PLACEBO_COMPARATOR | Administered for multiple dose |
| Name | Type | Description |
|---|---|---|
| HEC-007 injection | DRUG | Single dose escalation of HEC-007 injection in healthy subjects |
| Placebo | DRUG | Single dose of placebo in healthy adults |
Inclusion Criteria: SAD 1. Subjects understand and comply with the study procedures, voluntarily participate, and sign the informed consent form. 2. Healthy adult subjects (including borderline values) aged 18 to 45 years, regardless of sex. 3. Male subjects weigh no less than 50 kg, and female su...
HEC-007 is an investigational small molecule being studied for use in healthy subjects, including overweight or obese individuals. It is currently in a Phase 1 clinical trial to evaluate its safety, tolerability, and pharmacokinetic and pharmacodynamic profiles. The drug is administered as an injection.
HEC-007 is being developed by Sunshine Biopharma Inc., a company listed on the stock exchange under the ticker symbol SBFM. The company is conducting a Phase 1 clinical trial of HEC-007 injection in healthy and overweight or obese subjects in China.
HEC-007 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting participants to assess the safety, tolerability, and pharmacokinetic and pharmacodynamic properties of HEC-007 injection.
HEC-007 is being studied in a Phase 1 clinical trial with the identifier NCT07102251. The trial is titled 'A Study to Evaluate the Safety, Tolerability, PK/PD of HEC-007 Injection in Healthy and Overweight/Obese Subjects' and is currently recruiting participants in China. The study is randomized, double-blind, and placebo-controlled, with an enrollment of 126 subjects.
Yes, HEC-007 and HEC-007 injection refer to the same drug. The injection formulation is the form being evaluated in clinical trials. The drug is administered via injection and is being studied in healthy and overweight or obese subjects.